A Single-Dose, Placebo-Controlled, Stratified, Randomized, Double-Blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-Week Multiple-Dose Safety and Tolerability in People With Chronic Stable Schizophrenia.
Phase of Trial: Phase I/II
Latest Information Update: 03 Nov 2016
At a glance
- Drugs AQW 051 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2012 Actual patient number is 68 according to ClinicalTrials.gov.
- 24 Apr 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.